Therefore, current study aimed to evaluate the protective mechanism of G-CSF beyond the marrow cell mobilization and to clinically optimized G-CSF treatment strategy in NAFLD. The gene discussed is CSF3; the disease is metabolic dysfunction-associated steatotic liver disease.